{"id":"NCT01370499","sponsor":"Eli Lilly and Company","briefTitle":"A Study of LY2216684 in Participants With Major Depression Disorder","officialTitle":"Long-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Adult Patients With Major Depressive Disorder Who Were Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-08","primaryCompletion":"2014-01","completion":"2014-01","firstPosted":"2011-06-10","resultsPosted":"2018-10-25","lastUpdate":"2018-10-25"},"enrollment":288,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"LY2216684","otherNames":["Edivoxetine"]},{"type":"DRUG","name":"SSRI","otherNames":["Selective Serotonin Reuptake Inhibitor"]}],"arms":[{"label":"LY2216684 + SSRI","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the long-term safety and tolerability of LY2216684 administered once daily in the adjunctive treatment with an Selective Serotonin Reuptake Inhibitors (SSRI) for up to approximately 1 year in participants with Major Depressive Disorder (MDD) who were partial responders to their SSRI treatment.","primaryOutcome":{"measure":"Number of Participants With Clinically Significant Events","timeFrame":"Baseline through 52 weeks","effectByArm":[{"arm":"LY2216684 + SSRI (Placebo Prior Study)","deltaMin":0,"sd":null},{"arm":"LY2216684 + SSRI (LY2216684 Prior Study)","deltaMin":1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":21},"locations":{"siteCount":9,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":195},"commonTop":["Nasopharyngitis","Tachycardia","Palpitations","Hyperhidrosis","Nausea"]}}